Just some points to note re the phase II / III trial:
The CANVAS Trial now has @ 80 of 95 sites now recruiting or reading to recruit
- This is a significant number of the total sites being utilised for this trial.
Estimated enrollment is 1000 (clinicaltrials.gov)
- Statistically significant data can be reached for analysis upon relapse of
400 patients.
Estimated study completion - December 2015
- This is only 17 months away
Median survival of patients with recurrent ovarian cancer ranges from 12-24 months, demonstrating the chronic natural history of the disease
http://theoncologist.alphamedpress.org/content/7/suppl_5/20.full
- This is a poor prognosis which desperately needs a treatment other than
chemo or radiation therapy to expect life expectancy and improve quality
of life.
It seems that Prima may be expecting significant data for analysis as shown above, I hope that is the case anyway. The sooner this treatment (as long as it is shown to be of sufficient benefit as per the guidelines) is commercialised, the better.
- Forums
- ASX - By Stock
- IMM
- wakey wakey mr market
wakey wakey mr market, page-97
-
- There are more pages in this discussion • 307 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M |
Open | High | Low | Value | Volume |
30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 148547 | 32.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 51809 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 148547 | 0.320 |
3 | 107807 | 0.315 |
2 | 38192 | 0.310 |
2 | 58192 | 0.305 |
10 | 490669 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 44309 | 1 |
0.330 | 179497 | 6 |
0.335 | 82304 | 5 |
0.340 | 49303 | 3 |
0.345 | 27527 | 3 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online